The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report
Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or after sora...
Saved in:
Published in | Medicine (Baltimore) Vol. 97; no. 25; p. e11214 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health
01.06.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or after sorafenib treatment or patients who are intolerant of sorafenib remain an unmet medical need.
We report an advanced HCC patient with many lung metastases who failed sorafenib treatment.
Sorafenib refractory HCC patient with a large number of lung metastases.
The apatinib alone was used as second line therapy.
The patient achieved partial response (PR) soon after the treatment, which was maintained for approximately 1 year. During the entire process, the lung metastases continued to diminish. Finally, only a few lesions remained LESSONS:: Apatinib alone may be a good second-line therapy for advanced HCC patients who are refractory to sorafenib. However, further investigation in future prospective clinical studies is warranted. |
---|---|
AbstractList | Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or after sorafenib treatment or patients who are intolerant of sorafenib remain an unmet medical need.
We report an advanced HCC patient with many lung metastases who failed sorafenib treatment.
Sorafenib refractory HCC patient with a large number of lung metastases.
The apatinib alone was used as second line therapy.
The patient achieved partial response (PR) soon after the treatment, which was maintained for approximately 1 year. During the entire process, the lung metastases continued to diminish. Finally, only a few lesions remained LESSONS:: Apatinib alone may be a good second-line therapy for advanced HCC patients who are refractory to sorafenib. However, further investigation in future prospective clinical studies is warranted. RATIONALEHepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or after sorafenib treatment or patients who are intolerant of sorafenib remain an unmet medical need. PATIENT CONCERNSWe report an advanced HCC patient with many lung metastases who failed sorafenib treatment. DIAGNOSESSorafenib refractory HCC patient with a large number of lung metastases. INTERVENTIONSThe apatinib alone was used as second line therapy. OUTCOMESThe patient achieved partial response (PR) soon after the treatment, which was maintained for approximately 1 year. During the entire process, the lung metastases continued to diminish. Finally, only a few lesions remained LESSONS:: Apatinib alone may be a good second-line therapy for advanced HCC patients who are refractory to sorafenib. However, further investigation in future prospective clinical studies is warranted. |
Author | Zhao, Yaqin Ma, Xiaojun Duo, Ji Zhu, Hong |
AuthorAffiliation | b Department of Medical Oncology, The People's Hospital of Ganzi Tibetan Autonomous Prefecture, Sichuan, P.R. China a Department of Medical Oncology, West China Hospital, Sichuan University |
AuthorAffiliation_xml | – name: a Department of Medical Oncology, West China Hospital, Sichuan University – name: b Department of Medical Oncology, The People's Hospital of Ganzi Tibetan Autonomous Prefecture, Sichuan, P.R. China |
Author_xml | – sequence: 1 givenname: Hong surname: Zhu fullname: Zhu, Hong organization: Department of Medical Oncology, West China Hospital, Sichuan University Department of Medical Oncology, The People's Hospital of Ganzi Tibetan Autonomous Prefecture, Sichuan, P.R. China – sequence: 2 givenname: Xiaojun surname: Ma fullname: Ma, Xiaojun – sequence: 3 givenname: Yaqin surname: Zhao fullname: Zhao, Yaqin – sequence: 4 givenname: Ji surname: Duo fullname: Duo, Ji |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29924049$$D View this record in MEDLINE/PubMed |
BookMark | eNpdUctu1TAQtVARvS18ARLykk2KHdvJDQukquUltWJT1tbEGROjxA62U7g_wvfiqKU8ZjMa-Zwzx3NOyJEPHgl5ztkZZ1376vryjP0pzmsuH5EdV6KpVNfII7JjrFZV27XymJyk9LWARFvLJ-S47rpaMtntyM-bESn-MDhN6DMFn11e5xApWosm02ApLJCddz2FqRigkGhCE_xQTa6MecQIy4E6T4FuyE3mu8sjTSGCxUKsItoIJod4oCMWTNjWrRNEaiAa58MMr-l5GRLSiEuI-Sl5bGFK-Oy-n5LP797eXHyorj69_3hxflUZwVmuOPCmNgYUU_taqlaoXpo9F-UYsu-tVUMPLbP7BgYQpueW9aoZ9rJvrRDIrDglb-50l7WfcTDFfIRJL9HNEA86gNP_vng36i_hVjesFk3Li8DLe4EYvq2Ysp5d2r4HHsOadM1UK0XXsQ0q7qAmhpTKTR7WcKa3RPX1pf4_0cJ68bfDB87vCMUv1y6iCg |
Cites_doi | 10.1200/JCO.2015.63.5995 10.18632/oncotarget.20140 10.1200/JCO.2002.07.089 10.1056/NEJMoa0708857 10.1016/S1470-2045(04)01508-6 10.1080/15384047.2017.1323589 10.1200/JCO.2008.20.7753 10.1200/JCO.2013.48.8585 10.1097/MD.0000000000009598 10.18632/oncotarget.14724 10.1016/S1470-2045(08)70285-7 10.1016/S0140-6736(16)32453-9 10.1200/JCO.2012.45.8372 |
ContentType | Journal Article |
Copyright | Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018 |
Copyright_xml | – notice: Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1097/MD.0000000000011214 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1536-5964 |
EndPage | e11214 |
ExternalDocumentID | 10_1097_MD_0000000000011214 29924049 |
Genre | Journal Article Case Reports |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 0R~ 1CY 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ 8L- AAAAV AAGIX AAHPQ AAIQE AAMOA AAQKA AARTV AASCR AAWTL AAXQO AAYEP ABASU ABBUW ABCQX ABDIG ABFRF ABOCM ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB ADPDF AE3 AE6 AEFWE AENEX AFDTB AFFNX AFUWQ AGOPY AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJIOK AJNWD AJNYG AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 CGR CS3 CUY CVF DIWNM DU5 E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FD6 FIJ FL- FW0 GNXGY GQDEL GROUPED_DOAJ H0~ HLJTE HYE HZ~ H~9 IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C N4W N9A NPM N~7 N~B N~M O9- OAG OAH OB2 OCUKA ODA OHH OK1 OL1 OLB OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVEED OVIDH OVLEI OWU OWV OWW OWZ OXXIT P-K P2P R58 RIG RLZ RPM RXW S4R S4S T8P TAF TEORI TSPGW UNMZH V2I VVN W3M WOQ WOW X3V X3W X7M XXN XYM YFH YOC ZA5 ZFV ZGI ZXP ZY1 AAYXX AJZMW CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c310t-1a162cca5058245735b4c8131124bbff5dba70f86ada3cb1f0b56d84b7f33e0f3 |
IEDL.DBID | RPM |
ISSN | 0025-7974 |
IngestDate | Tue Sep 17 21:18:04 EDT 2024 Fri Aug 16 07:39:04 EDT 2024 Fri Aug 23 01:19:50 EDT 2024 Thu May 23 23:35:45 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 25 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c310t-1a162cca5058245735b4c8131124bbff5dba70f86ada3cb1f0b56d84b7f33e0f3 |
Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023671/ |
PMID | 29924049 |
PQID | 2057439901 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6023671 proquest_miscellaneous_2057439901 crossref_primary_10_1097_MD_0000000000011214 pubmed_primary_29924049 |
PublicationCentury | 2000 |
PublicationDate | 2018-06-01 |
PublicationDateYYYYMMDD | 2018-06-01 |
PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Medicine (Baltimore) |
PublicationTitleAlternate | Medicine (Baltimore) |
PublicationYear | 2018 |
Publisher | Wolters Kluwer Health |
Publisher_xml | – name: Wolters Kluwer Health |
References | Bruix (R4-81-20210404) 2017; 389 Li (R6-81-20210404) 2016; 34 Burroughs (R10-81-20210404) 2004; 5 Liu (R9-81-20210404) 2017; 8 Altekruse (R1-81-20210404) 2009; 27 Llovet (R2-81-20210404) 2008; 359 Li (R5-81-20210404) 2013; 31 Lu (R8-81-20210404) 2017; 18 Poon (R12-81-20210404) 2002; 20 Kou (R13-81-20210404) 2017; 8 Cheng (R3-81-20210404) 2009; 10 Zhu (R7-81-20210404) 2018; 97 Cheng (R11-81-20210404) 2013; 31 |
References_xml | – volume: 34 start-page: 1448 year: 2016 ident: R6-81-20210404 article-title: Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction publication-title: J Clin Oncol doi: 10.1200/JCO.2015.63.5995 contributor: fullname: Li – volume: 8 start-page: 100734 year: 2017 ident: R9-81-20210404 article-title: Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study publication-title: Oncotarget doi: 10.18632/oncotarget.20140 contributor: fullname: Liu – volume: 20 start-page: 1775 year: 2002 ident: R12-81-20210404 article-title: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study publication-title: J Clin Oncol doi: 10.1200/JCO.2002.07.089 contributor: fullname: Poon – volume: 359 start-page: 378 year: 2008 ident: R2-81-20210404 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 contributor: fullname: Llovet – volume: 5 start-page: 409 year: 2004 ident: R10-81-20210404 article-title: Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum publication-title: Lancet Oncol doi: 10.1016/S1470-2045(04)01508-6 contributor: fullname: Burroughs – volume: 18 start-page: 433 year: 2017 ident: R8-81-20210404 article-title: Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial publication-title: Cancer Biol Ther doi: 10.1080/15384047.2017.1323589 contributor: fullname: Lu – volume: 27 start-page: 1485 year: 2009 ident: R1-81-20210404 article-title: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.7753 contributor: fullname: Altekruse – volume: 31 start-page: 3219 year: 2013 ident: R5-81-20210404 article-title: Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial publication-title: J Clin Oncol doi: 10.1200/JCO.2013.48.8585 contributor: fullname: Li – volume: 97 start-page: e9598 year: 2018 ident: R7-81-20210404 article-title: The radiosensitive effect of apatinib for hepatocellular carcinoma patient with big paraspinal metastasis: a case report publication-title: Medicine doi: 10.1097/MD.0000000000009598 contributor: fullname: Zhu – volume: 8 start-page: 20510 year: 2017 ident: R13-81-20210404 article-title: Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review publication-title: Oncotarget doi: 10.18632/oncotarget.14724 contributor: fullname: Kou – volume: 10 start-page: 25 year: 2009 ident: R3-81-20210404 article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70285-7 contributor: fullname: Cheng – volume: 389 start-page: 56 year: 2017 ident: R4-81-20210404 article-title: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32453-9 contributor: fullname: Bruix – volume: 31 start-page: 4067 year: 2013 ident: R11-81-20210404 article-title: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.8372 contributor: fullname: Cheng |
SSID | ssj0013724 |
Score | 2.3350399 |
Snippet | Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard... RATIONALEHepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | e11214 |
SubjectTerms | Adult Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Chemoembolization, Therapeutic - methods Clinical Case Report Disease Progression Fatal Outcome Humans Liver Neoplasms - diagnostic imaging Liver Neoplasms - drug therapy Liver Neoplasms - pathology Lung - diagnostic imaging Lung - microbiology Lung - pathology Lung Neoplasms - diagnostic imaging Lung Neoplasms - pathology Lung Neoplasms - secondary Male Neoplasm Metastasis - drug therapy Niacinamide - administration & dosage Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - administration & dosage Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pyridines - administration & dosage Pyridines - pharmacology Pyridines - therapeutic use Sorafenib Tomography, X-Ray Computed - methods |
Title | The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29924049 https://search.proquest.com/docview/2057439901 https://pubmed.ncbi.nlm.nih.gov/PMC6023671 |
Volume | 97 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBbaDhh2GfZu1i7QgB3nJrYkyzkOTYpigLcd1qE3g5IlNEAjF4kDrL9gf7ukbQV93OarX7JJmx-ljx8Z-yI05ggzUImgr1AayBJTg01gBuhR0tTCU-1w-SM_v5DfL9XlHlOxFqYj7VuzPAnXq5OwvOq4lTcrO4k8scmv8jQn2XOdTvbZvhYipuhx6UBnctenFdFylBqa6Uk57-UK-w2RRkptefCHjGGNxDTvR6YncPMxa_JeGDp7xV4O-JF_68f5mu258IY9L4cV8rfsH9qdu7_dfHxoOVAV7nbVrHlP3OCN50Ak6rA0HK6b4Dhs-Iay4johxMn7gqxbvgwc-KC6ymm2lm_QW7zDExMc-7rr03PLrzCctQ3djvis3FJrotCs4B27OFv8Pj1PhmYLiUWE1yYppHlmqUGCKjKptFBG2oLEeDJpjPeqNqCnvsihBmFN6qdG5XUhjfZCuKkX79lBwFEfUhm4wrxMOiMx3ZGpI00_KWxtBChZez9iX-OLrm56TY0qroWX8-qxiUbsczRGhb5PTwTBNdtNlSHYpHxqmo7Yh944uwtGq46YfmC23QGkq_1wD7pbp689uNfH_z7ziL1AXFX0jLJjdtCut-4TYpfWjLucf8ye_fyzWMzHnefeAXm38Yc |
link.rule.ids | 230,315,733,786,790,870,891,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKkYAL5auwUMBIHMnuJrbj7BH1Qws0FYcW9RbZjq2u6DrVblai_AH-NjNxvGq3J8g1cRJnxvEb-80bQj4yCTHCRImE4SjkWmWJrpVJ1ESBR3FdM4e5w-VJPj3jX8_F-RYRMRemI-0bPRv6y_nQzy46buXV3IwiT2z0vdzPUfZcpqN75D6M10zGID1uHsiMryu1Al6OYkMTOSoPgmBhOABrpFiYB37JMLGhnObNuekO4NzkTd6YiI52yI_YhcA_-TlctXpofm-oO_5zH5-Qxz00pZ_D6adky_pn5EHZb74_J3_Apaj91S31-5YqTPBdzZsFDZwQ2jiqkJ_tZ5qqy8ZbqpZ0iQF3nSCYpSHX65rOPFW0F3SluBBMl-CIzkLDBD7KoisBdE0vYKZsG3wcUmWpwapHvpmrF-Ts6PB0f5r0dRwSA-CxTVKV5pnB2guiyLiQTGhuCtT5ybjWzolaKzl2Ra5qxYxO3ViLvC64lo4xO3Zsl2x7eOtXmGEuIOTjVnOIpHhqUS6QM1NrpgSvnRuQT9GC1VWQ66jiNnt5UG3afkA-RCtXMKywR8rbZrWsMsCxGKqN0wF5Gay-vmF0lwGRt_xhfQFKdt8-A1bupLt7q77-75bvycPpaXlcHX85-faGPAL4VgTi2h7Zbhcr-xYgUqvfdQPiL-8CEPw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkSouvCmBFhaJI45j767tHKuGqDxc9UCliou1TzWiWUeJI1H-AH-bGa8dpemtvtprez2z3m92v_mGkE8shxhhLEXEcBRyJdNIGakjOZbgUVwZ5jB3uDzLTi_4t0txuVXqqyXtazUb-uv50M-uWm7lYq7jnicWn5cnGcqe50m8MC5-SB7BmE3HfaDebyDkKd9UawXM3AsOjfO4nATRwnAA3kiwOA_8lmFyQ0nN7fnpDujc5U5uTUbTp-RX343AQfk9XDdqqP_uKDzeq5_PyJMOotLjcMlz8sD6F2S_7DbhX5J_4FrU_mmX_H1DJSb6ruf1kgZuCK0dlcjT9jNF5XXtLZUrusLA20QIamnI-bqhM08l7YRdKS4I0xU4pLPQMIIPs2xLAd3QK5gxmxofh5RZqrH6ka_n8hW5mH75eXIadfUcIg0gsokSmWSpxhoMoki5yJlQXBeo95NypZwTRsl85IpMGsm0StxIicwUXOWOMTty7DXZ8_DWbzDTXEDox63iEFHxxKJsIGfaKCYFN84NyOfeitUiyHZU_XZ7Oal27T8gH3tLVzC8sEfS23q9qlLAsxiyjZIBOQiW39ywd5kByW_5xOYClO6-fQYs3Up4d5Z9e--WH8j--WRa_fh69v0deQworgj8tUOy1yzX9giQUqPet2PiP3VqE3w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+excellent+antitumor+effect+of+apatinib+alone+as+second-line+therapy+in+a+patient+with+sorafenib-refractory+hepatocellular+carcinoma&rft.jtitle=Medicine+%28Baltimore%29&rft.au=Zhu%2C+Hong&rft.au=Ma%2C+Xiaojun&rft.au=Zhao%2C+Yaqin&rft.au=Duo%2C+Ji&rft.date=2018-06-01&rft.issn=0025-7974&rft.volume=97&rft.issue=25&rft.spage=e11214&rft_id=info:doi/10.1097%2FMD.0000000000011214&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_MD_0000000000011214 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0025-7974&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0025-7974&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0025-7974&client=summon |